Welcome to our dedicated page for Omnicell news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell stock.
Omnicell Inc. (OMCL) is a pioneering company that has been enhancing efficiencies in healthcare since 1992. As a leading supplier of comprehensive automation and business analytics software, Omnicell focuses on patient-centric medication and supply management across the entire healthcare continuum. This includes acute care hospital settings, post-acute skilled nursing and long-term care facilities, as well as home care settings.
Omnicell's automated hardware/software systems for medication dispensing provide seamless solutions from the point of hospital entry to the central pharmacy, nursing units, operating rooms, and patient bedsides. Their supply management systems are designed to promote cost control, ensure charge capture for payer reimbursement, and facilitate efficient inventory management and reordering.
Omnicell's range of products includes high-security, closed-cabinet systems, open-shelf systems, and combination systems that are used in nursing units, cath labs, and operating rooms. These solutions empower pharmacists and nurses to concentrate on patient care rather than administrative tasks, driving improved clinical, operational, and financial outcomes across diverse care settings. With over 3,200 customers worldwide, Omnicell continues to be a trusted partner in the healthcare sector.
In recent years, Omnicell has made significant strides in advancing their technology and expanding their service offerings. Their commitment to innovation is evident in the development of new products and partnerships that aim to further streamline medication management processes. Financially, the company generates the majority of its revenue in the United States, reflecting a strong market presence and consistent performance.
EnlivenHealth, a division of Omnicell (OMCL), has launched a new Scope of Practice and Reimbursement Snapshot solution for Good Neighbor Pharmacy members. This innovative tool provides critical information on clinical services and reimbursement tailored to each state, empowering independent pharmacies to expand their clinical offerings and improve patient care.
The solution offers easy access to up-to-date information on approved clinical services, reimbursement activities, and medical billing codes. It aims to simplify the complex landscape of clinical services and billing, potentially driving operational efficiency and revenue growth for pharmacies. Good Neighbor Pharmacy members can access the solution through their AB Solutions Portal.
Omnicell (NASDAQ:OMCL) announced strong Q2 2024 results, exceeding guidance across all metrics. Total revenues were $277 million, down 7% year-over-year. GAAP net income was $0.08 per diluted share, while non-GAAP net income reached $0.51 per diluted share. The company reported $557 million in cash and cash equivalents and $571 million in total debt. Omnicell raised its 2024 non-GAAP EBITDA and earnings per share guidance, projecting full-year revenues between $1.070 billion and $1.110 billion. The company's XT Amplify program is gaining market momentum, and strategic partnerships are enhancing pharmacy performance. Omnicell remains focused on innovation and streamlining operations to drive long-term growth and shareholder returns.
Omnicell, Inc. (Nasdaq:OMCL), a leader in pharmacy care delivery transformation, has announced the release of its second quarter 2024 financial results on August 1, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Interested parties can join the call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 internationally, using the Conference ID 3278878. A live and archived webcast will be available on Omnicell's Investor Relations website.
Omnicell, Inc. (OMCL) will be presenting at the BofA Securities 2024 Health Care Conference in Las Vegas, NV. The presentation will take place on May 15, 2024, at 3:40 p.m. PT. The event will be live-streamed and available for viewing on the Omnicell website.
Omnicell, Inc. (NASDAQ:OMCL) announced first quarter 2024 results, exceeding guidance with total GAAP revenues of $246 million. The company reported a challenging environment for some health system customers affecting revenues. Omnicell highlighted new solutions for their XT automated dispensing systems and ongoing efforts to enhance shareholder value. Financially, the company reported a net loss of $16 million, non-GAAP net income of $1 million, and non-GAAP EBITDA of $11 million. With a strong balance sheet, Omnicell aims to transform the pharmacy care delivery model and continues to innovate in the industry.
FAQ
What is the current stock price of Omnicell (OMCL)?
What is the market cap of Omnicell (OMCL)?
What is Omnicell Inc. known for?
When was Omnicell Inc. founded?
What types of healthcare settings does Omnicell serve?
How do Omnicell's products benefit healthcare providers?
What kinds of products does Omnicell offer?
How many customers does Omnicell have globally?
Where does Omnicell generate most of its revenue?
What recent achievements has Omnicell made?
How do Omnicell's supply management systems aid healthcare facilities?
What is the primary goal of Omnicell's products and services?
